Technology evaluation: ABX-EGF, Abgenix/Amgen.
Abgenix and Amgen (formerly Immunex) are developing ABX-EGF, a human monoclonal antibody against the epidermal growth factor receptor, for potential use in the treatment of cancer. ABX-EGF is undergoing phase II trials in patients with renal, colorectal, prostate and non-small-cell lung cancers. By July 2002, phase III trials for these indications were planned to start in 2003.
University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK. malcolm.ranson@man.ac.uk
Malcolm
M
Ranson
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab; D066246:ErbB Receptors